The once-monthly drug is still under study but could provide added convenience and another option for patients.

The weight loss and diabetes drug, which is only available on prescription, should be on pharmacy shelves within days ending ...

Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

Novo Nordisk A/S (NYSE:NVO) saw its stock decline 2.1% in premarket trading after Spain’s health ministry initiated an ...

US Health Secretary Kennedy says HHS to launch campaign to encourage wearable devices – Nation and World News | West Hawaii Today ...

Berger Montague, a nationally recognized securities litigation firm, is investigating potential claims on behalf of investors who purchased or otherwise acquired securities of Hims ...

A massive U.S. study found diabetics on semaglutide (Ozempic’s active ingredient) had up to 70% lower risk of ...

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

In a statement on Monday, Amgen Inc. (NASDAQ:AMGN) announced that its phase 2 study of its weight loss drug candidate, ...

A $10.2 million savings across more than 100,000 prescriptions over three months, extrapolated across the nearly 33 million Americans currently taking GLP-1 medications monthly, indicates a potential ...